Maki Goto

Publications (3)9.2 Total impact

• Article: Identification of autoantibodies expressed in acquired aplastic anaemia.

  Maki Goto, Kageaki Kuribayashi, Yusuke Takahashi, Takashi Kondoh, Maki Tanaka, Daisuke Kobayashi, Naoki Watanabe
  [show abstract] [hide abstract]
  ABSTRACT: Acquired aplastic anaemia (aAA) is recognized as an autoimmune disorder; however, the autoantigens and target cells involved remain elusive. Expression of autoantibodies and their target cells were examined using the haematopoietic cell line K562 and bone marrow stromal cell line hTS-5; 43·5% and 21·7% of aAA expressed autoantibody against K562 and hTS-5 cells, respectively. The autoantigens were identified by serological identification of antigens through recombinant cDNA expression cloning. This study indicates that haematopoietic cells are the targets of immune abnormality in aAA. These autoantibodies may be utilized to distinguish patients associated with immune abnormality from bone marrow failure syndrome.
  British Journal of Haematology 11/2012; · 4.94 Impact Factor
• Article: High prevalence of human anti-mouse antibodies in the serum of colorectal cancer patients.

  Maki Goto, Kageaki Kuribayashi, Yoshifumi Umemori, Yui Ohe, Koichi Asanuma, Maki Tanaka, Daisuke Kobayashi, Naoki Watanabe
  [show abstract] [hide abstract]
  ABSTRACT: Monoclonal antibody treatment induces the expression of human anti-mouse antibodies (HAMA), which in turn interfere with the therapy. However, whether HAMAs are expressed before the initiation of antibody therapy in patients with colorectal cancer remains unknown. Serum samples were collected from 40 patients diagnosed with colorectal cancer. Serum samples from 157 individuals without cancer were used as controls. None of the patients received imaging or therapeutic antibodies before the study. The expression of HAMAs was evaluated by ELISA with murine immunoglobulin G1 (mIgG)1, mIgG2a and mIgG2b as the antigen. Of the 40 colorectal cancer patients, 9 (22.5%) expressed either IgG- or IgM-type HAMAs while only 13/157 (8.2%) of the individuals without cancer expressed the HAMAs (p<0.05). HAMAs are prevalent in the serum of colorectal cancer patients even before antibody administration. Medical practitioners should be alert to the possibility of HAMA expression when administering antibody therapy.
  Anticancer research 10/2010; 30(10):4353-6. · 1.73 Impact Factor
• Article: Prevalence of human anti-mouse antibodies (HAMAs) in routine examinations.

  Saori Koshida, Koichi Asanuma, Kageaki Kuribayashi, Maki Goto, Naoki Tsuji, Daisuke Kobayashi, Maki Tanaka, Naoki Watanabe
  [show abstract] [hide abstract]
  ABSTRACT: Circulating heterophilic antibodies interfere with immunological assays in laboratory examinations; however, their rate of incidence is currently questionable. We developed an enzyme-linked immunosorbent assay (ELISA) to detect human anti-mouse antibodies (HAMAs) in routine examinations. The study samples were comprised of serum samples obtained from 290 inpatients and outpatients at our hospital. Mouse immunoglobulin G1 (mIgG1), mIgG2a, and mIgG2b were used as the antigens and horseradish peroxidase (HRP)-conjugated anti-human IgG and IgM were used to identify the HAMA isotype. HAMAs were detected in 11.7% (34/290) of the samples. We observed 18 and 20 samples positive for IgG- and IgM-type HAMAs, respectively. Four samples contained both IgG- and IgM-type HAMAs. HAMAs against mIgG1, mIgG2a, and mIgG2b were found in 21, 14, and 13 samples, respectively. Existence of HAMAs was confirmed by western blotting using mIgG's as the antigens and HAMAs as the primary antibodies. Heterophilic blocking reagent (HBR) was also used to block the heterophilic interactions. Unexpectedly, a low HBR concentration rather enhanced the interactions instead of blocking them. A considerable number of HAMA-positive samples, reacting with the heavy chain of mIg, were found in routine examinations. A sufficient amount of HBR should be used for blocking the heterophilic interactions.
  Clinica chimica acta; international journal of clinical chemistry 12/2009; 411(5-6):391-4. · 2.54 Impact Factor